This mini-review authored by Prof. Chaitan Khosla and coworkers at Stanford University (CA, USA) provides a
concise overview of natural product inhibitors of the glucose-6-phosphate translocase (G6P T1) system.
Non-insulin dependant diabetes (type II) and carcinogenesis are two major diseases in which abberant glucose levels are observed, and for which glucose-6-phosphate translocase could be a promising therapeutic target. Enzyme G6P T1 hydrolyses glucose-6-phosphate to glucose, which is then released into the bloodstream: modulating its activity may prove an attractive therapeutic strategy.
Following an overview of the role of glucose-6-phosphate translocase in human physiology and its potential as a therapeutic target, the review covers its Natural Product inhibitors, including:
- Chlorogenic acid and chlorogenic acid derivatives
- Phloretin
- Salicilic acid derived G6P T1 inhibitors
- Kodaistatins
- Mumbaistatins and Mumbaistatins derivatives
Natural product inhibitors of glucose-6-phosphate translocase
Louise K. Charkoudian, Bailey P. Farrell and Chaitan Khosla
Med. Chem. Commun., 2012
Access the article by Chaitan Khosla et al. – Access the full collection on Natural Products
